← Back to Search

3D Perfusion Ultrasound for Liver Cancer

N/A
Waitlist Available
Led By Daniel T. Chang
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (pre-treatment), 0-7 days post treatment, 2-4 months post treatment.
Awards & highlights

Study Summary

This trial will use 3D ultrasound to study how well it can help plan radiation treatment for liver tumors, predict how well the treatment will work, and monitor how the tumor responds to treatment.

Eligible Conditions
  • Liver Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (pre-treatment), 0-7 days post treatment, 2-4 months post treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-treatment), 0-7 days post treatment, 2-4 months post treatment. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in Blood Perfusion (Blood Volume)
Changes in Blood Perfusion (Mean Flow Velocity)
Changes in Blood Perfusion (Relative Blood Flow)

Trial Design

1Treatment groups
Experimental Treatment
Group I: 3D Perfusion UltrasoundExperimental Treatment2 Interventions
undergo 3D ultrasound perfusion imaging with perflutren
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
perflutren lipid microspheres
2007
N/A
~20
3D ultrasound
2007
N/A
~150

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,386 Previous Clinical Trials
17,333,997 Total Patients Enrolled
9 Trials studying Liver Cancer
997 Patients Enrolled for Liver Cancer
Daniel T. ChangPrincipal InvestigatorStanford University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation
2014. "Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02424955.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top